Theranos: Governance and Verification Breakdown

What The Source Case Actually Shows

The CAMP source case for Theranos is explicit: this is a framework-limit case where major claims were fraudulent, not merely optimistic. The executive summary states that core technology validity failed while external confidence remained high for a prolonged period.

The case still offers practical value because it shows where diligence should have concentrated earlier: technical verification pathways, governance independence, and evidence traceability for high-impact claims.

CAMP Gap From Apparent To Actual

• Apparent pillar profile in the source: Capital 80, Advantage 85, Market 75, People 70.
• Actual pillar profile in the same source model: Capital 80, Advantage 0, Market 75, People 10.
• Weighted CAMP in the source comparison table: 76.75 apparent vs 52.0 actual.

The delta is the key lesson. Strong narrative optics can preserve an apparent score long after operational reality has deteriorated if evidence controls are weak.

Operator Lens For Founders

Institutionalize a claims-evidence ledger before scale. For every product, clinical, or performance statement, define source evidence, validation owner, and review cadence. This discipline protects both fundraising credibility and long-term trust capital.